Prediction of PSA Progression in Castrate-Resistant Prostate Cancer based on Treatment-Associated Change in Tumor Burden Quantified by 18F-fluorocholine PET/CT

Metabolically active tumor volume (MATV) measurements can be applied to (18)F-fluorocholine positron emission tomography/computed tomography (PET/CT) to quantify whole-body tumor burden. This study evaluates the serial application of these measurements as systemic treatment response markers and predictors of disease progression in patients with castrate-resistant prostate cancer (CRPC).

METHODS - Forty-two patients completed sequential (18)F-fluorocholine PET/CT scans before and 1 to 3 months after starting treatment for CRPC. Whole-body tumor segmentation was applied to determine net MATV from each scan. Changes in net MATV were evaluated as predictors of time to PSA progression by Kaplan-Meier and proportional hazards regression analysis.

RESULTS - Treatments consisted of chemotherapy in 16 patients, anti-androgens in 19 patients, (223)Ra-dichloride in 5 patients, and sipuleucel-T in 2 patients. A significant MATV response (defined as a 30% or greater decrease in net MATV) was observed in 20 patients based on in-treatment PET/CT performed an average (median) of 52 (49) days into treatment. Significantly longer times to PSA progression were observed in patients that exhibited a MATV response (418 days vs. 116 days, P = 0.007). MATV response was associated with a hazard ratio of 0.246 (P = 0.01116) for PSA progression, which remained significant when adjusted for treatment type.

CONCLUSIONS - Significant changes in whole-body tumor burden can be measured on (18)F-fluorocholine PET/CT over the course of contemporary treatments for CRPC. In this study, these changes were found to be predictive of PSA progression as a potential surrogate marker of treatment outcome. Because (18)F-fluorocholine PET/CT can also be used for localizing resistant tumors, this modality can potentially complement other measures of response in the precision management of advanced prostate cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Feb 16 [Epub ahead of print]

Joo Hee Lee, Miles Sato, Marc N Coel, Kyung-Han Lee, Sandi Kwee

Samsung Medical Center, Korea, Republic of;, The Queen's Medical Center, United States;, The Queen's Medical Center, United States;, Sungkyunkwan University School of Medicine, Korea, Republic of., The Queen's Medical Center, United States;


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.